Published in Gastroenterology on July 02, 2011
Spironolactone Therapy In Young Women With NASH | NCT03576755
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther (2012) 3.25
Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature (2014) 2.30
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis (2014) 1.56
Declining liver graft quality threatens the future of liver transplantation in the United States. Liver Transpl (2015) 1.50
Underestimation of liver-related mortality in the United States. Gastroenterology (2013) 1.46
Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci (2014) 1.45
Functional impairment in older liver transplantation candidates: From the functional assessment in liver transplantation study. Liver Transpl (2015) 1.43
Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun (2016) 1.41
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest (2017) 1.36
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology (2015) 1.18
Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.17
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2013) 1.12
Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle (2012) 1.08
Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis (2012) 1.06
Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med (2015) 1.06
Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol (2014) 1.02
Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol (2014) 1.01
Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol (2014) 0.98
The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis (2012) 0.97
Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am J Physiol Endocrinol Metab (2013) 0.95
Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol (2014) 0.92
Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut (2014) 0.91
Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am (2016) 0.90
Diagnosis and Management of Alcoholic Liver Disease. J Clin Transl Hepatol (2015) 0.89
Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample. Am J Transplant (2016) 0.89
Effect of dietary advanced glycation end products on mouse liver. PLoS One (2012) 0.89
Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition? Hepatology (2012) 0.88
Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut (2015) 0.88
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.88
The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci (2016) 0.88
Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. PPAR Res (2012) 0.86
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology (2016) 0.85
Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int (2015) 0.85
Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol (2014) 0.85
Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. Transplantation (2014) 0.85
Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci (2016) 0.85
Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab (2014) 0.84
Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances. World J Gastroenterol (2013) 0.84
Keys to long-term care of the liver transplant recipient. Nat Rev Gastroenterol Hepatol (2015) 0.83
A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice. PLoS One (2013) 0.83
Spinal cord injury causes chronic liver pathology in rats. J Neurotrauma (2014) 0.83
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open (2013) 0.83
Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases. J Clin Transl Hepatol (2015) 0.83
Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet. PLoS One (2015) 0.83
Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol (2014) 0.83
Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2016) 0.83
Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol (2013) 0.82
Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci (2017) 0.82
The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci (2015) 0.82
External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One (2015) 0.82
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol (2014) 0.82
Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol (2015) 0.82
Diabetes mellitus, and not obesity, is associated with lower survival following liver transplantation. Dig Dis Sci (2015) 0.82
Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. JAMA Pediatr (2016) 0.82
Current and Future Burden of Chronic Nonmalignant Liver Disease. Clin Gastroenterol Hepatol (2015) 0.81
Perceptions of non-alcoholic fatty liver disease - an Asian community-based study. Gastroenterol Rep (Oxf) (2015) 0.81
NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol (2016) 0.81
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol (2012) 0.81
Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One (2015) 0.81
Management of non-alcoholic fatty liver disease in 2015. World J Hepatol (2015) 0.81
Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.81
Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. Dig Dis Sci (2016) 0.81
Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci (2016) 0.80
Recipient ineligibility after liver transplantation assessment: a single centre experience. Can J Surg (2013) 0.80
Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci (2016) 0.80
Liver transplantation and sleeve gastrectomy in the medically complicated obese: New challenges on the horizon. World J Hepatol (2015) 0.80
Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol (2015) 0.80
Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells. BMC Complement Altern Med (2014) 0.80
A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol (2012) 0.80
Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol (2014) 0.80
Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats. BMC Pharmacol Toxicol (2016) 0.79
Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol (2015) 0.79
Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? PLoS One (2014) 0.79
Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci (2013) 0.79
Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis. PLoS One (2013) 0.79
Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol (2014) 0.79
The role of everolimus in liver transplantation. Clin Exp Gastroenterol (2014) 0.79
Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival. Curr Opin Organ Transplant (2016) 0.78
Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database. PLoS One (2016) 0.78
Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. BMC Gastroenterol (2015) 0.78
The future liver of the Asia pacific: fatter and firmer from more fructose and fortune? J Clin Exp Hepatol (2012) 0.78
Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol (2015) 0.78
Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. World J Transplant (2014) 0.78
Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci (2016) 0.78
Nonalcoholic Fatty Liver Disease Is Associated With QT Prolongation in the General Population. J Am Heart Assoc (2015) 0.78
Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology (2016) 0.77
Liver injury and fibrosis induced by dietary challenge in the Ossabaw miniature Swine. PLoS One (2015) 0.77
Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep (2014) 0.77
Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice. Int J Obes (Lond) (2016) 0.77
Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol (2015) 0.77
Insulin resistance in type 2 diabetic youth. Curr Opin Endocrinol Diabetes Obes (2012) 0.77
PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum. J Clin Transl Hepatol (2016) 0.77
Posttransplant metabolic syndrome. Int J Hepatol (2012) 0.76
New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology (2013) 2.76
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol (2003) 2.47
Normal intraabdominal pressure in healthy adults. J Surg Res (2005) 2.34
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl (2012) 2.14
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst (2002) 2.13
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis (2008) 2.12
Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl (2007) 1.76
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
The insensitivity of endoscopic markers in celiac disease. Am J Gastroenterol (2002) 1.70
Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl (2007) 1.64
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology (2011) 1.59
Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl (2011) 1.58
Liver transplantation for cholangiocarcinoma. Transpl Int (2010) 1.58
Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology (2013) 1.50
Training in small-bowel capsule endoscopy: assessing and defining competency. Gastrointest Endosc (2013) 1.50
Incidence, prevalence, and survival of chronic pancreatitis: a population-based study. Am J Gastroenterol (2011) 1.48
Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology (2009) 1.35
Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol (2012) 1.33
Autoimmune hepatitis: a review of current diagnosis and treatment. Hepat Res Treat (2011) 1.24
HLA DQ gene dosage and risk and severity of celiac disease. Clin Gastroenterol Hepatol (2007) 1.22
Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice. Hepatology (2012) 1.21
Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology (2009) 1.18
Textile analysis of heavy weight, mid-weight, and light weight polypropylene mesh in a porcine ventral hernia model. J Surg Res (2006) 1.17
Endoscopic ultrasound staging of cholangiocarcinoma. Curr Opin Gastroenterol (2012) 1.16
Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. Mayo Clin Proc (2012) 1.14
Long-term fracture risk in patients with celiac disease: a population-based study in Olmsted County, Minnesota. Dig Dis Sci (2007) 1.12
Occurrence of and risk factors for complications after endoscopic dilation in eosinophilic esophagitis. Gastrointest Endosc (2010) 1.10
Free fatty acid storage in human visceral and subcutaneous adipose tissue: role of adipocyte proteins. Diabetes (2011) 1.09
Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am (2009) 1.08
The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation (2012) 1.08
Predicting failure of outpatient laparoscopic cholecystectomy. Am J Surg (2002) 1.08
CXC chemokine signaling in the liver: impact on repair and regeneration. Hepatology (2011) 1.07
Burden of de novo malignancy in the liver transplant recipient. Liver Transpl (2012) 1.07
Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl (2007) 1.07
The usefulness of routine small bowel biopsies in evaluation of iron deficiency anemia. J Clin Gastroenterol (2004) 1.04
Donor race does not predict graft failure after liver transplantation. Gastroenterology (2010) 1.03
Liver transplantation for perihilar cholangiocarcinoma. Dig Dis (2013) 1.02
Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology (2012) 1.01
Arterial baroreflex control of heart rate during exercise in postural tachycardia syndrome. J Appl Physiol (1985) (2007) 1.00
Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary? J Am Coll Surg (2012) 0.99
International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation (2016) 0.99
Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantation. Transplantation (2010) 0.99
Personality characteristics of health care satisfaction survey non-respondents. Int J Health Care Qual Assur (2009) 0.99
Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol (2009) 0.97
Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology (2012) 0.97
Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis (2012) 0.96
Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. Liver Transpl (2014) 0.95
Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol (2008) 0.93
Survival after liver transplantation: Is racial disparity inevitable? Hepatology (2007) 0.93
Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology (2012) 0.93
A learning needs assessment of patients with COPD. Medsurg Nurs (2006) 0.92
Patient localization of esophageal dysphagia. Dig Dis Sci (2004) 0.90
Receptor activator of nuclear factor-κB ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice. Hepatology (2012) 0.88
Celiac disease in type 1 diabetes mellitus in a North American community: prevalence, serologic screening, and clinical features. Mayo Clin Proc (2005) 0.88
Excellent long-term patient and graft survival are possible with appropriate use of livers from deceased septuagenarian and octogenarian donors. HPB (Oxford) (2014) 0.88
Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol (2013) 0.87
Living donor kidney transplantation using laparoscopically procured multiple renal artery kidneys and right kidneys. J Am Coll Surg (2013) 0.87
The diagnosis of esophageal eosinophilia is not increased in the summer months. Dysphagia (2014) 0.87
Risk of cancer in autoimmune pancreatitis: a case-control study and review of the literature. Pancreas (2014) 0.87
Long-term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc (2012) 0.86
Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology (2010) 0.86
Outcome of lung transplantation in elderly recipients. Eur J Cardiothorac Surg (2010) 0.85
Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy. Ann Pharmacother (2013) 0.84
Patient and graft outcomes from older living kidney donors are similar to those from younger donors despite lower GFR. Kidney Int (2004) 0.84
Minimally invasive management of colon cancer. Surg Innov (2006) 0.84
Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant (2007) 0.84
Observer variability in the histologic diagnosis of microscopic colitis. Inflamm Bowel Dis (2009) 0.84
Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology (2017) 0.83
Antibody-mediated rejection in liver transplantation: current controversies and future directions. Liver Transpl (2014) 0.83
Patients dismissed from the hospital with a diagnosis of noncardiac chest pain: cardiac outcomes and health care utilization. Mayo Clin Proc (2010) 0.83
Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl (2013) 0.83
APACHE III outcome prediction in patients admitted to the intensive care unit after liver transplantation: a retrospective cohort study. BMC Surg (2009) 0.83
Risk and predictors of cardiovascular disease in psoriasis: a population-based study. Int J Dermatol (2013) 0.83
Outcomes and challenges in implementing hourly rounds to reduce falls in orthopedic units. Worldviews Evid Based Nurs (2011) 0.82
The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation (2011) 0.82
Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl (2012) 0.82
Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int (2013) 0.82
Gastric antral injections of botulinum toxin delay gastric emptying but do not reduce body weight. Clin Gastroenterol Hepatol (2012) 0.82
Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. Liver Transpl (2013) 0.81
Light exposure among adolescents with delayed sleep phase disorder: a prospective cohort study. Chronobiol Int (2011) 0.81
Nonalcoholic steatohepatitis in bariatric patients with a diagnosis of obstructive sleep apnea. Obes Facts (2012) 0.81
Employment and health insurance in long-term liver transplant recipients. Am J Transplant (2005) 0.81
Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. Gut Liver (2010) 0.80
Using implantation biopsies as a surrogate to evaluate selection criteria for living kidney donors. Transplantation (2013) 0.80
The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int (2013) 0.80
Risk Factors for Dexmedetomidine-Associated Hemodynamic Instability in Noncardiac Intensive Care Unit Patients. Anesth Analg (2016) 0.80
Laparoscopic cholecystectomy in the cirrhotic patient: predictors of outcome. Surgery (2013) 0.79
Early allograft dysfunction in liver transplantation with donation after cardiac death donors results in inferior survival. Liver Transpl (2014) 0.79
Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival. Curr Opin Organ Transplant (2016) 0.78
Early subclinical coronary artery calcification in young adults who were pediatric kidney transplant recipients. Am J Transplant (2005) 0.78